This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronaryarterydisease. Peripheralarterialdisease ( PAD ) affects more than 200 million people worldwide. Glob Heart. 2014;9(1):145-158 e121. 2013;382(9901):1329-1340.
CLTI is the most severe form of peripheralarterialdisease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). For more information: www.biotronik.com References: 1 Kwong M.,
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronaryarterydisease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronaryarterydisease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronaryarterydisease (CAD) and peripheralarterydisease (PAD).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content